What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin are synthetic peptides that stimulate the body’s natural release of growth hormone.

CJC-1295 mimics growth hormone-releasing hormone (GHRH), signaling the pituitary gland to release growth hormone.
Ipamorelin works through ghrelin receptors to stimulate growth hormone release.

Together, they may support muscle recovery, body composition, and growth hormone signaling. Individual results vary, and use should be guided by a qualified healthcare professional.

Why Are CJC-1295 and Ipamorelin Used Together?

CJC-1295 and Ipamorelin work through different pathways to stimulate growth hormone release:

CJC-1295 provides longer-acting stimulation of the growth hormone pathway.
Ipamorelin promotes a more direct release of growth hormone from the pituitary gland.

When combined, they are intended to provide complementary stimulation of growth hormone release. Clinical evidence supporting the benefits of this combination remains limited.

Dosing and administration

CJC-1295 and ipamorelin are typically administered by subcutaneous injection into areas such as the abdomen, thigh, or upper arm.

Frequency: Dosing schedules vary and should be determined by a healthcare professional.
Timing: Often administered in the evening, based on the body’s natural growth hormone patterns.
Treatment Duration: Treatment protocols vary depending on individual goals and clinical assessment.

Results vary by individual, and the safety and effectiveness of CJC-1295/ipamorelin combinations have not been fully established in clinical studies.

Potential Side Effects & Risks

CJC-1295 and ipamorelin may cause side effects, including:

Injection-site reactions: Redness, swelling, or discomfort.
Flushing or warmth: Temporary changes in blood pressure or heart rate may occur.
Headache or flu-like symptoms: Mild symptoms may occur in some individuals.
Allergic reactions: Peptides may trigger immune or allergic reactions, including rare serious reactions.
Cancer considerations: Growth hormone–stimulating therapies may not be appropriate for individuals with active cancer or certain cancer histories.

BACK

Psychiatric Mental Health Practice

New Bridges Psychiatry, LLC

Est. 2026

What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin are synthetic peptides that stimulate the body’s natural release of growth hormone.

CJC-1295 mimics growth hormone-releasing hormone (GHRH), signaling the pituitary gland to release growth hormone.

Ipamorelin works through ghrelin receptors to stimulate growth hormone release.

Together, they may support muscle recovery, body composition, and growth hormone signaling. Individual results vary, and use should be guided by a qualified healthcare professional.

Why Are CJC-1295 and Ipamorelin Used Together?

CJC-1295 and Ipamorelin work through different pathways to stimulate growth hormone release:

CJC-1295 provides longer-acting stimulation of the growth hormone pathway.

Ipamorelin promotes a more direct release of growth hormone from the pituitary gland.

When combined, they are intended to provide complementary stimulation of growth hormone release. Clinical evidence supporting the benefits of this combination remains limited.

Dosing and administration

CJC-1295 and ipamorelin are typically administered by subcutaneous injection into areas such as the abdomen, thigh, or upper arm.

Frequency: Dosing schedules vary and should be determined by a healthcare professional.

Timing: Often administered in the evening, based on the body’s natural growth hormone patterns.

Treatment Duration: Treatment protocols vary depending on individual goals and clinical assessment.

Results vary by individual, and the safety and effectiveness of CJC-1295/ipamorelin combinations have not been fully established in clinical studies.

Potential Side Effects & Risks

CJC-1295 and ipamorelin may cause side effects, including:

Injection-site reactions: Redness, swelling, or discomfort.

Flushing or warmth: Temporary changes in blood pressure or heart rate may occur.

Headache or flu-like symptoms: Mild symptoms may occur in some individuals.

Allergic reactions: Peptides may trigger immune or allergic reactions, including rare serious reactions.

Cancer considerations: Growth hormone–stimulating therapies may not be appropriate for individuals with active cancer or certain cancer histories.

CJC-1295 / Ipamorelin

What Are CJC-1295 and Ipamorelin?

​

CJC-1295 and Ipamorelin are synthetic peptides that stimulate the body’s natural release of growth hormone.

CJC-1295 mimics growth hormone-releasing hormone (GHRH), signaling the pituitary gland to release growth hormone.

Ipamorelin works through ghrelin receptors to stimulate growth hormone release.

Together, they may support muscle recovery, body composition, and growth hormone signaling. Individual results vary, and use should be guided by a qualified healthcare professional.

Why Are CJC-1295 and Ipamorelin Used Together?

CJC-1295 and Ipamorelin work through different pathways to stimulate growth hormone release:

CJC-1295 provides longer-acting stimulation of the growth hormone pathway.

Ipamorelin promotes a more direct release of growth hormone from the pituitary gland.

When combined, they are intended to provide complementary stimulation of growth hormone release. Clinical evidence supporting the benefits of this combination remains limited.

Dosing and administration

CJC-1295 and ipamorelin are typically administered by subcutaneous injection into areas such as the abdomen, thigh, or upper arm.

Frequency: Dosing schedules vary and should be determined by a healthcare professional.

Timing: Often administered in the evening, based on the body’s natural growth hormone patterns.

Treatment Duration: Treatment protocols vary depending on individual goals and clinical assessment.

Results vary by individual, and the safety and effectiveness of CJC-1295/ipamorelin combinations have not been fully established in clinical studies.

Potential Side Effects & Risks

CJC-1295 and ipamorelin may cause side effects, including:

Injection-site reactions: Redness, swelling, or discomfort.

Flushing or warmth: Temporary changes in blood pressure or heart rate may occur.

Headache or flu-like symptoms: Mild symptoms may occur in some individuals.

Allergic reactions: Peptides may trigger immune or allergic reactions, including rare serious reactions.

Cancer considerations: Growth hormone–stimulating therapies may not be appropriate for individuals with active cancer or certain cancer histories.

CJC-1295 / Ipamorelin